tricyclic antidepressants + selective serotonin reuptake inhibitors

This entry refers to the combination therapy of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), two distinct classes of antidepressant medications. TCAs, such as amitriptyline and imipramine, act primarily by inhibiting the reuptake of both serotonin and norepinephrine, increasing their levels in the brain[1][2]. SSRIs, including fluoxetine and sertraline, selectively inhibit the reuptake of serotonin alone[8]. The rationale for combining these drugs is to potentially enhance antidepressant efficacy in treatment-resistant depression by targeting multiple neurotransmitter systems simultaneously[5][6]. However, this combination can lead to significant pharmacokinetic interactions—SSRIs may increase TCA blood levels via inhibition of cytochrome P450 2D6 metabolism—raising the risk for adverse effects such as cardiac toxicity or serotonergic side effects[6][9]. This approach is generally reserved for cases where monotherapy has failed due to limited evidence supporting its routine use and concerns about safety.